A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid Dependent Asthma (TROPOS)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms TROPOS
- Sponsors AstraZeneca
- 19 Jun 2017 Planned primary completion date changed from 7 Jun 2017 to 13 Sep 2017.
- 10 Jun 2017 Biomarkers information updated
- 15 Nov 2016 Planned End Date changed from 1 Oct 2017 to 1 Sep 2017.